I was recently asked the following question:
Jamie
What is your view on the treatment of prize funds? By all standards it is treated as a radical off the wall proposal when in fact it is market based. Why is there so much resistance?
My response was as follows:
In a letter dated 4 May 2010, the Director General of the World Trade Organization (WTO), Pascal Lamy has responded to questions and concerns of the European Parliament regarding the Anti Counterfeiting Trade Agreement (ACTA). Continue Reading
The Chapter FIVE (Institutional Arrangements) of ACTA is short. In less than 4 pages (pp 33-36) the negotiators “hereby establish” and “Oversight Steering Committee” (the OSC). Of course all of this chapter can be revisited later (see footnote 73) but let’s examine what is proposed now.
KEI has issued a new research note, Comments on ACTA Provisions on Injunctions and Damages, KEI Research Note 2010:1, dated April 6, 2010.
In looking at how enforcement norms are being changed in ACTA, it is helpful to review the enforcement chapter of NAFTA.
KEI has access to yet undisclosed sections of the negotiating ACTA text. The text is organized in 6 chapters. The longest is Chapter 2 on “legal framework for enforcement of intellectual property rights.” The second longest is Chapter 5, on “Institutional Arrangements.” In ten pages of text, the ACTA negotiators have set out a plan to create a new institution to administer, implement and modify ACTA. Continue Reading
Below are asks from the 2010 PhRMA submission to the USTR Special 301 list on the topic of drug pricing and reimbursement decisions, and described as ‘Market Access Barriers.’ In its assertions, PhRMA attack countries for government price negotiations, making use of reference pricing, the insufficient involvement of pharmaceutical companies in setting government pricing policies and the composition of drug formularies, among other things.
CHINA
2010
On July 28, 2006, Jeffrey Kindler replaced Hank McKinnell as CEO of Pfizer. That day the Pfizer stock price closed at $26.11. With the stock trading today at a little more than $17, it would seem that shareholders have lost a significant amount of their investment. Nonetheless, Kindler is doing well.
The following are a few notes on PhRMA’s revolving door with the federal government.
Billy Tauzin. Former member of Congress from Louisiana.
Chris Singer. Previously served as a professional staff member for the U.S. House Appropriations Committee.
Brian Toohey. Former Desk Officer and Deputy Director in the European Office of the U.S. Department of Commerce.